Legend Biotech
LEGN
19.12
+0.40
+2.14%
Legend Biotech
US · LEGN
#2374 by market cap
Listed 2020
19.12
+0.40
+2.14%
Live - 5344 symbols - heartbeat 206s ago
· 2026-10-08 06:23
Pre-market
19.19
+0.37%
After-hours
19.20
+0.42%
Overnight
19.25
+0.68%
- Market cap
- 3.72B
- P/E (TTM)i
- -38.24
- P/Bi
- 3.02
- EPSi
- -1.62
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on LEGN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
45.41 +137.5%
Price target rangecurrent 19.12
Low24.00
Avg45.41
High74.00
Buy 56%
Hold 44%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-02 | UBS | -- | HOLD | 24.00 |
| 2026-09-30 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-09-28 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-09-11 | Barclays | -- | BUY | 74.00 |
| 2026-09-09 | RBC Capital | -- | BUY | 58.00 |
| 2026-09-04 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-08-13 | UBS | -- | HOLD | 28.00 |
| 2026-08-12 | TD Cowen | -- | HOLD | 24.00 |
| 2026-08-12 | Morgan Stanley | -- | BUY | 48.00 |
| 2026-08-12 | Goldman Sachs | -- | BUY | 40.70 |
| 2026-08-12 | Oppenheimer | -- | HOLD | 40.00 |
| 2026-08-11 | TD Cowen | -- | HOLD | 24.00 |
| 2026-08-11 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-08-11 | Barclays | -- | BUY | 78.00 |
| 2026-08-11 | RBC Capital | -- | BUY | 58.00 |
| 2026-07-28 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-07-27 | RBC Capital | -- | BUY | 59.00 |
| 2026-07-24 | UBS | -- | HOLD | 28.00 |
| 2026-07-16 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-07-15 | Goldman Sachs | -- | BUY | 40.50 |
| 2026-07-15 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-07-14 | Barclays | -- | BUY | 80.00 |
| 2026-07-13 | J.P. Morgan | -- | HOLD | 35.00 |
| 2026-07-07 | RBC Capital | -- | BUY | 63.00 |
| 2026-06-25 | Goldman Sachs | -- | BUY | 41.42 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
4
■ Upgrades■ Downgrades
- 0 upgrades vs 4 downgrades among tracked analyst rating changes.
- Most recent: Oppenheimer moved from Buy to Hold on 2026-08-12.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-12 | Oppenheimer | BUY → HOLD | 40.00 |
| 2026-07-24 | UBS | BUY → HOLD | 28.00 |
| 2026-07-13 | J.P. Morgan | BUY → HOLD | 35.00 |
| 2026-01-22 | TD Cowen | BUY → HOLD | 21.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-11 | -- | ±8.77% | +5.66% (in line) |
| 2026/Q1 | 2026-05-12 | -- | ±9.03% | +10.48% (beat) |
| 2025/Q4 | 2026-03-10 | -- | ±8.97% | +2.19% (in line) |
| 2025/Q3 | 2025-11-12 | -- | ±8.98% | -2.67% (in line) |
| 2025/Q2 | 2025-08-11 | -- | ±10.07% | -2.05% (in line) |
| 2025/Q1 | 2025-05-13 | -- | ±10.87% | -4.01% (in line) |
| 2024/Q3 | 2024-11-12 | -- | ±8.20% | +0.35% (in line) |
| 2024/Q2 | 2024-08-09 | -- | ±14.01% | -1.77% (in line) |
| 2024/Q1 | 2024-05-13 | -- | ±11.01% | -0.62% (in line) |
| 2023/Q4 | 2024-03-11 | -- | ±11.96% | +3.07% (in line) |
| 2023/Q3 | 2023-11-20 | -- | ±11.65% | -6.29% (in line) |
| 2023/Q2 | 2023-08-15 | -- | ±10.11% | -4.83% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:23:44 · For reference only, not investment advice and not tailored to your situation.